ClinicalTrials.gg
CompletedNCT03830866CALLAUpdated Jul 26, 2024Results posted

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

A Phase 3 interventional study of Durvalumab and Cisplatin in Locally Advanced Cervical Cancer, sponsored by AstraZeneca. Completed at 117 sites in 15 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
770
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Uterine Cervical Neoplasms by AstraZeneca — 3 open to participants now, 5 under way, 1 of them phase 3. Uterine Cervical Neoplasms · AstraZeneca.

Started
2019
with 1 other
Phase 3
2 of 11
1 open now
Registered
3rd of 11
by date

Among the 11 studies in Uterine Cervical Neoplasms by AstraZeneca, this one is one of 2 that started in 2019, is one of 2 in phase 3, and was the 3rd registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

3 of the 11 studies in Uterine Cervical Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Uterine Cervical Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer

Read the detailed description

Women will be randomized in a 1:1 ratio to receive treatment with concurrent durvalumab + standard of care (SoC) or Placebo + Soc, followed by durvalumab/placebo maintenance for 24 months.

03

Conditions studied

  • Locally Advanced Cervical Cancer

Keywords

  • Durvalumab
  • Chemoradiotherapy
  • Locally Advanced Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study, patients should fulfill the following criteria:

  1. Female
  2. Aged at least 18 years
  3. Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO (2009) Stages IB2 to IIB node positive or FIGO (2009) IIIA-IVA any node
  4. No prior chemotherapy or radiotherapy for cervical cancer
  5. performance status of 0-1
  6. At least 1 lesion, not previously irradiated, that qualifies as a 1.1 Target Lesion at baseline.

Exclusion criteria

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Diagnosis of small cell (neuroendocrine) histology or mucinous adenocarcinoma cervical cancer
  2. Intent to administer a fertility-sparing treatment regimen
  3. Undergone a previous hysterectomy
  4. Evidence of disease per 1.1 including lymph nodes ≥15 mm (short axis) above the L1 cephalad body, in the inguinal region or outside the planned radiation field.
  5. History of allogeneic organ transplantation
  6. Active or prior documented or inflammatory disorders
  7. Uncontrolled intercurrent illness
  8. History of another primary and active primary immunodeficiency
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
770 participants (actual)

Study arms

  • Experimental
    Durvalumab (intravenous infusion)

    durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization

    Biological: Durvalumab · Drug: Cisplatin · Drug: Carboplatin · Radiation: external beam radiation therapy (EBRT) + brachytherapy

  • Placebo comparator
    Placebo (matching placebo for intravenous infusion)

    placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)

    Drug: Cisplatin · Drug: Carboplatin · Radiation: external beam radiation therapy (EBRT) + brachytherapy

Interventions

  • BiologicalDurvalumab

    IV infusion every 4 weeks

  • Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy

  • For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy

  • Radiationexternal beam radiation therapy (EBRT) + brachytherapy

    Radiation therapy per standard of care

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression

    PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression

    Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months

Secondary outcomes

  1. Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1%

    PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression

    Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months

  2. Overall Survival (Count)

    Number of Participants with Overall Survival (OS) where OS was defined as the time from the date of randomisation until death by any cause

    Time frame: Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months

  3. Overall Survival (Duration)

    Time from the date of randomisation until death by any cause

    Time frame: Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months

  4. Objective Response Rate (ORR)

    Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target and non-target lesions and no new lesions. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion

    Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months

  5. Complete Response Rate

    Percentage of evaluable patients with an overall visit response of Complete Response (disappearance of all target and non-target lesions)

    Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months

  6. Duration of Response (DoR) in Patients With Complete Response (CR)

    Time from date of first documented CR until date of documented progression or death in the absence of progression. For patients who did not progress their DoR was their Progression-free survival censoring time

    Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months

07

Results

Posted Mar 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneDurvalumab + SoC CCRTPlacebo + SoC CCRT
Started385385
Completed268249
Not completed117136
Withdrew: Death90111
Withdrew: Lost to follow-up77
Withdrew: Withdrawal by subject1916
Withdrew: No longer eligible due to additional cancer diagnosis01
Withdrew: Other11

Outcome measures

PrimaryProgression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression

PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression

Time frame:
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Reported as:
Median · Months
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression
MonthsDurvalumab + SoC CCRTPlacebo + SoC CCRT
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour ProgressionNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Durvalumab + SoC CCRT vs Placebo + SoC CCRT · Log Rank · p = 0.174 · Hazard ratio (hr): 0.84 · 95% CI 0.65 to 1.08
SecondaryProgression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1%

PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression

Time frame:
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Reported as:
Median · Months
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1%
MonthsDurvalumab + SoC CCRTPlacebo + SoC CCRT
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1%NA (NA to NA)NA (26.9 to NA)
Statistical analysis
  • Durvalumab + SoC CCRT vs Placebo + SoC CCRT · Log Rank · p = 0.203 · Hazard ratio (hr): 0.84 · 95% CI 0.64 to 1.10
SecondaryOverall Survival (Count)

Number of Participants with Overall Survival (OS) where OS was defined as the time from the date of randomisation until death by any cause

Time frame:
Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
Reported as:
Count of participants · Participants
Overall Survival (Count)
ParticipantsDurvalumab + SoC CCRTPlacebo + SoC CCRT
Died91112
Censored (includes subjects who withdrew consent and subjects who were lost to follow up)294273
SecondaryOverall Survival (Duration)

Time from the date of randomisation until death by any cause

Time frame:
Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
Reported as:
Median · Months
Overall Survival (Duration)
MonthsDurvalumab + SoC CCRTPlacebo + SoC CCRT
Overall Survival (Duration)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Durvalumab + SoC CCRT vs Placebo + SoC CCRT · Log Rank · p = 0.091 · Hazard ratio (hr): 0.79 · 95% CI 0.60 to 1.04
SecondaryObjective Response Rate (ORR)

Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target and non-target lesions and no new lesions. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion

Time frame:
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsDurvalumab + SoC CCRTPlacebo + SoC CCRT
Objective Response Rate (ORR)82.680.5
Statistical analysis
  • Durvalumab + SoC CCRT vs Placebo + SoC CCRT · Regression, Logistic · p = 0.465 · Odds ratio (or): 1.15 · 95% CI 0.794 to 1.657
SecondaryComplete Response Rate

Percentage of evaluable patients with an overall visit response of Complete Response (disappearance of all target and non-target lesions)

Time frame:
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Reported as:
Number · Percentage of Participants
Complete Response Rate
Percentage of ParticipantsDurvalumab + SoC CCRTPlacebo + SoC CCRT
Complete Response Rate42.940.3
Statistical analysis
  • Durvalumab + SoC CCRT vs Placebo + SoC CCRT · Regression, Logistic · p = 0.469 · Odds ratio (or): 1.11 · 95% CI 0.833 to 1.487
SecondaryDuration of Response (DoR) in Patients With Complete Response (CR)

Time from date of first documented CR until date of documented progression or death in the absence of progression. For patients who did not progress their DoR was their Progression-free survival censoring time

Time frame:
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Reported as:
Median · Months
Duration of Response (DoR) in Patients With Complete Response (CR)
MonthsDurvalumab + SoC CCRTPlacebo + SoC CCRT
Duration of Response (DoR) in Patients With Complete Response (CR)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over From the time of signature of informed consent throughout the treatment period (median duration of 656 and 532 days for durvalumab and placebo respectively) up to and including the 90-day safety follow-up period following the last dose of study treatment, up to a maximum of 53 months (Data cut-off date of 03Jul2023). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durva + SoC CCRT91/385 (23.6%)113/385 (29.4%)373/385 (96.9%)
Placebo + SoC CCRT112/385 (29.1%)90/384 (23.4%)368/384 (95.8%)
Most frequent serious events
Showing 10 of 156
Most frequent serious events
EventDurva + SoC CCRTPlacebo + SoC CCRT
AnaemiaBlood and lymphatic system disorders20/38520/384
Urinary tract infectionInfections and infestations16/38511/384
Vaginal haemorrhageReproductive system and breast disorders7/3855/384
Acute kidney injuryRenal and urinary disorders6/3853/384
Abdominal painGastrointestinal disorders6/3852/384
Radiation proctitisInjury, poisoning and procedural complications6/3852/384
Febrile neutropeniaBlood and lymphatic system disorders5/3851/384
HypokalaemiaMetabolism and nutrition disorders1/3854/384
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/3854/384
PneumoniaInfections and infestations1/3854/384
Most frequent other events
Showing 10 of 54
Most frequent other events
EventDurva + SoC CCRTPlacebo + SoC CCRT
NauseaGastrointestinal disorders213/385202/384
AnaemiaBlood and lymphatic system disorders209/385200/384
DiarrhoeaGastrointestinal disorders177/385190/384
VomitingGastrointestinal disorders105/385107/384
ConstipationGastrointestinal disorders97/38587/384
Urinary tract infectionInfections and infestations90/38592/384
Decreased appetiteMetabolism and nutrition disorders89/38564/384
Neutrophil count decreasedInvestigations74/38585/384
White blood cell count decreasedInvestigations71/38585/384
NeutropeniaBlood and lymphatic system disorders74/38555/384

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Durvalumab + SoC CCRTPlacebo + SoC CCRTTotal
Mean49.6 ± 11.7448.8 ± 11.6749.2 ± 11.70
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab + SoC CCRTPlacebo + SoC CCRTTotal
Female385385770
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + SoC CCRTPlacebo + SoC CCRTTotal
White130125255
Black or African American101222
Asian152148300
American Indian or Alaska Native4756103
Other464490
08

Study locations

117 sites
  • Research Site
    Phoenix, Arizona 85016, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Fort Myers, Florida 33905, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Augusta, Georgia 30912, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    Cleveland, Ohio 44111, United States
  • Research Site
    Cleveland, Ohio 44124, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Spring, Texas 77380, United States
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Porto Alegre, 90050-170, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20220-410, Brazil
  • Research Site
    Sao Paulo, 01317-000, Brazil
  • Research Site
    Sao Paulo, 01509-900, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Antofagasta, 1267348, Chile
  • Research Site
    Santiago, 7500921, Chile
  • Research Site
    Santiago, 7630370, Chile
  • Research Site
    Santiago, 8380455, Chile
  • Research Site
    Temuco, 4810218, Chile
  • Research Site
    Temuco, 4810469, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 100003, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Tianjin, 300052, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Ahmedabad, 380015, India
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Madurai, 625107, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Nagpur, 440026, India
  • Research Site
    Nashik, 422002, India
  • Research Site
    New Delhi, 110063, India
  • Research Site
    Vishakhapatnam, 530017, India
  • Research Site
    Fukuoka-shi, 811-1395, Japan
  • Research Site
    Kagoshima-shi, 890-8520, Japan
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Kyoto-shi, 606-8507, Japan
  • Research Site
    Nakagami-gun, 903-0215, Japan
  • Research Site
    Osaka-shi, 541-8567, Japan
  • Research Site
    Sapporo-shi, 003-0804, Japan
  • Research Site
    Sendai-shi, 980-8574, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Toon-shi, 791-0204, Japan
  • Research Site
    Yokohama-shi, 236-0004, Japan
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 08826, Korea, Republic of
  • Research Site
    Alc. Cuauhtémoc, 06700, Mexico
  • Research Site
    Deleg. Tlalpan, 14080, Mexico
  • Research Site
    Guadalajara Jalisco, 44280, Mexico
  • Research Site
    Guadalajara, 44680, Mexico
  • Research Site
    Mérida, 97134, Mexico
  • Research Site
    San Luis Potosí, 78250, Mexico
  • Research Site
    Veracruz, 91900, Mexico
  • Research Site
    Lima, L27, Peru
  • Research Site
    Lima, LIMA 27, Peru
  • Research Site
    Lima, LIMA 31, Peru
  • Research Site
    Lima, LIMA 34, Peru
  • Research Site
    Lima, LIMA 41, Peru
  • Research Site
    Baguio City, 2600, Philippines
  • Research Site
    Cebu, 6000, Philippines
  • Research Site
    Iloilo, 5000, Philippines
  • Research Site
    Makati, 1229, Philippines
  • Research Site
    Manila, 1015, Philippines
  • Research Site
    Quezon City, 1112, Philippines
  • Research Site
    Bialystok, 15-027, Poland
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Gliwice, 44-101, Poland
  • Research Site
    Lublin, 20-090, Poland

Showing the first 100 of 117 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mayadev J, Nunes AT, Li M, Marcovitz M, Lanasa MC, Monk BJ. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020 Jul;30(7):1065-1070. doi: 10.1136/ijgc-2019-001135. Epub 2020 May 23. PubMed 32447296 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jan 2022, 35 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 35 months is close to that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2018
First posted
Feb 5, 2019
StartActual
Feb 15, 2019
Primary completionActual
Jan 20, 2022
CompletionActual
Jul 3, 2023
Results first posted
Mar 6, 2023
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03830866
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 5, 2019
Start date
Feb 15, 2019
Primary completion
Jan 20, 2022
Completion
Jul 3, 2023
Results posted
Mar 6, 2023
Last update
Jul 26, 2024

Study contacts

Urban Scheuring, M.D., Ph.D.
study director · AstraZeneca
Bradley Monk, M.D
principal investigator · University of Arizona, Arizona, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion